Elicio Therapeutics director gets 21,750 options

Rhea-AI Filing Summary

Elicio Therapeutics, Inc. (ELTX) reported that director and ten percent owner Yekaterina Chudnovsky received a grant of stock options for 21,750 shares of common stock on August 31, 2026, at an exercise price of $2.70 per share, held as a direct derivative position.

The options represent her annual non-employee director equity award and will vest and become exercisable in full on the earlier of August 31, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service, and expire on August 31, 2036. No additional equity award will be made to her in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 21,750 shares

Grant/Award 1 txn

Insider Chudnovsky Yekaterina

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	21,750	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,750 contracts (Direct)

Footnotes (1)

1. F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Key Figures

Option Shares Granted: 21,750 shares Exercise Price: $2.70 per share Options Held After Grant: 21,750 options +3 more

6 metrics

Option Shares Granted 21,750 shares Stock option grant to director and ten percent owner on August 31, 2026

Exercise Price $2.70 per share Conversion or exercise price of the stock options

Options Held After Grant 21,750 options Total derivative securities directly owned by the reporting person following the transaction

Grant Date August 31, 2026 Date the stock options were granted

Vesting Date Latest August 31, 2027 Latest possible date for full vesting, or earlier at 2027 annual meeting

Expiration Date August 31, 2036 Expiration of the stock option term

Key Terms

Stock Option, annual non-employee director equity award, vest and become exercisable, expiration date

4 terms

Stock Option financial

"The stock option represents the annual non-employee director equity award"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

annual non-employee director equity award financial

"The stock option represents the annual non-employee director equity award"

vest and become exercisable financial

"and shall vest and become exercisable in full on the earlier of"

expiration date financial

"expiration_date": "2036-08-31""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did ELTX grant to Yekaterina Chudnovsky?

Elicio Therapeutics granted Yekaterina Chudnovsky a stock option for 21,750 shares of common stock as her annual non-employee director equity award on August 31, 2026.

What is the exercise price of the new ELTX stock options?

The granted stock options have an exercise price of $2.70 per share, allowing purchase of up to 21,750 shares of Elicio Therapeutics common stock upon vesting and exercise.

When do the newly granted ELTX options vest for the director?

The options will vest and become exercisable in full on the earlier of August 31, 2027, or the 2027 annual meeting of stockholders, provided the director continues to provide services through the vesting date.

When do the director’s new ELTX stock options expire?

The stock options granted to the director expire on August 31, 2036, giving a ten-year term from the August 31, 2026 grant date.

Will ELTX grant any additional equity award to the director for the 2026 meeting?

No. The company states that no additional equity award will be made to the director in connection with the 2026 annual meeting of stockholders beyond this option grant.

Were the ELTX option transactions made under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan applies to this stock option grant to the director and ten percent owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:05 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chudnovsky Yekaterina

(Last) (First) (Middle)

C/O ELICIO THERAPEUTICS, INC.

451 D STREET, 5TH FLOOR, SUITE 501

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.7	08/31/2026		A		21,750		(1)	08/31/2036	Common Stock	21,750	$0	21,750	D

Explanation of Responses:

1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Remarks:

	/s/ Yekaterina Chudnovsky	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)